Member Info for Karlvonwise

Well with Labour's green target and housing project, this could become very promising

Sometimes it doesn't hurt to say what if .

So ignor the noise and hold x

They certainly know how to nobble a stock.

🚨 **Beware of Stock Rampers!** 🚨

Before you jump on the latest "can't-miss" stock tip, remember: some posters are just out to pump up prices and then dump their shares, leaving you in the dust. Always do your own research and make informed decisions. Stay smart, invest wisely! 💡📈

Very quiet here today, does that mean the penny has dropped when the rampers dawned on them theat the institutions are now in control of this stock, hence why they in the words of one particular ramper 'were giving them money'

News flash if someone wants to give you money , look under the table first

Rampers are still using the same old "fear of missing out" tactics. I'm not saying you shouldn't invest here, but be prepared to get burned.

The reason why there are stull private investors here , is because our investment has dwindled through inept actions and pointless to leave with the hope of success n the horizon.

Potential movement today ?

The buys outweigh the sells but we still in the red ???

GG,

Another point to consider is that everyone is excited about institutions allegedly buying 85% of the placement, which now significantly outnumbers private investors. What’s to stop these institutions from taking control of Aptamer, putting it into private hands, and reaping the rewards? These institutions didn’t become wealthy without reason. So, forgive me if I’m not eager to join you in this venture.

@GG Oh, bless your heart! You've got quite a talent for spiteful little jabs and even littler words.

I asked a civil question, but all you can muster is name-calling.

Is this why your mum didn’t let you join LSE, or are we dealing with daddy issues here?

The real concern is your habit of making assumptions. Where in the RNS does it say 'it might be sold to some chum'?

By the way, the share price is holding steady at 0.20, the dilution price. News flash: most shares—99% except CLP—maintain their value post-dilution.

So, today's lesson is that your comments are as reliable as a chocolate teapot.

@1408, you are quite correct. It seems I'm not interpreting the data the same way you are, which is why we can't seem to agree. However, I do share your and GG's thoughts on patience. Time often reveals the truth and clears up the mysteries of the present.

If you want to convince me to buy this share, answer this: With the share price so low, we can agree it's a bargain. So why is it still so low after so many placements? Are the company custodians inept at securing funding, or are the market makers taking advantage?

@GG, unlike some, I genuinely hope for the best and sincerely hope that you are right and I am wrong.

@GG, unlike some, I genuinely hope for the best and sincerely hope that you are right and I am wrong.

Yes 1408 your post are pure classics of the golden age......

Previous post ....'you won't get a sniff at this price,'

You right there fella, it's dropping already

As I mentioned before, why not explore loans, convertible notes, and other financing methods? Diluting the shares means diluting the crown jewels. When you dilute shareholders' equity, you're limiting your future funding options. There are many ways to secure financing, but share dilution shouldn't be one of them. If anything goes wrong now, all funding avenues might dry up, and the company could return to private ownership.

Regarding share consolidation, the company would first need to buy back its shares, which would potentially raise the share price to about 0.60 if it bought back a billion shares. For example, if Aptamer bought back a billion shares at 0.20 per share, they would need £2 million, more than they made last year. To stay afloat, they need to make £4.9 million in profit and an additional £3 million for share consolidation, assuming a 2-for-1 share price rise to 0.60 per share.

In essence, Aptamer needs to make at least £8 million next year to regain prominence. I don't see them reaching that level. The real question is when will shareholders feel the pain. I am a shareholder too, but I can't recommend others invest heavily in this stock, as it is not being managed well financially, in my opinion.

The only sunlight I see is future contracts especially in organ transplant but we have to wait and see.

My thoughts are my own, biotech companies can be lucrative investments but remember OCTP who decided their shares were worth more and so delisted.

Hey, cape crusader GG, still hanging around? Looks like everyone else is making a mad dash before August 14th. Or have you joined the great escape too?

Dan55

I tend to agree with you, Dan, but Nigel has made a smart move by partnering with SRI International. Let's face it—Nigel can now relax while SRI handles all the commercialization efforts.

Price: 0.45

No Opinion

RE: Is anything going on?26 Jul 2024 11:35

Such small buys my guess is someone trying to get the price up then sell out once the price raises but markets not falling for it . Can’t see any news coming in as Nigel got his money from the placing until he runs out of

At present you cannot even sell on H&L that's how demanding these shares are at present.

My concern is our cape crusader GG who has taken 2 decades to join lse failed to grasp the arithmetic of dilution

@GG 50 post wonder

Well, GG, it's impressive how you manage to sound so spiteful with only 50 posts to your name. It's like you've joined just to invite others to leap into the abyss, all while proclaiming the company's impending success. You seem to be yelling from the rooftops about how fantastic the company is, yet somehow, it's still struggling to make a profit. Bravo for that unique combination of optimism and oblivion!

@GG

In investing, especially in volatile sectors like biotech, it's crucial to base decisions on comprehensive research and clear financial indicators rather than speculative posts.

Its important to keep critical eye on the company's financial health and strategic moves .

My concerns with the financial health is more critical due to point why the dilution all the time , why not loans or c notes.

Interestingly posters claim the share price to raise to 0.50 then for them to bail at 0.35

I seen many companies wander down this road diluting and diluting only then it goes into administration .

Aptamer Group last year , undergone two equity placings totaling £3.5 million to stabilize its finances and extend its operational runway. However, whether the company will rebound or continue to face challenges is uncertain and depends on several factors.

The company has faced significant challenges, including a steep decline in its share price and financial instability. Despite securing new contracts and partnerships, Aptamer Group has struggled to achieve profitability. This has led to ongoing concerns about potential further dilution of shares to raise additional funds. It has now diluted again at 1.6 Billion shares.

The wise Investors are cautious,. This sentiment is fueled by the fact that the company's revenue increases have not yet led to profitability, and further ability to raise equity will be unachievable.

On the optimistic side, Aptamer Group has secured partnerships with significant players like Unilever and Microsaic Systems, which could boost its future prospects. If these collaborations lead to substantial revenue growth, the company might stabilize and potentially see a rebound its share price.

In conclusion, while there is hope for a rebound due to strategic partnerships and new contracts, the immediate outlook remains cautious. The company's ability to raise further funds and achieve profitability will be crucial in determining its future trajectory.

At present the trajectory has been in free fall, and if Aptamer Group follows the pattern of other companies with promising products but an inability to achieve profitability, it risks delisting or being acquired at a low price, which could significantly disadvantage private investors.